AVXL (Anavex Life Sciences) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Anavex Life Sciences Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Anavex Life Sciences's net issuance of preferred for the three months ended in Dec. 2024 was $0.00 Mil. The number is 0, which means that Anavex Life Sciences has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Anavex Life Sciences's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Anavex Life Sciences Net Issuance of Preferred Stock Historical Data

The historical data trend for Anavex Life Sciences's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences Net Issuance of Preferred Stock Chart

Anavex Life Sciences Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Anavex Life Sciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Anavex Life Sciences Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Anavex Life Sciences Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Anavex Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (NAS:AVXL) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

0HFR:UK 12X1:Germany 12X1:Germany

Address

630 5th Avenue, 20th Floor, New York, NY, USA, 10111

Website

https://www.anavex.com

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Executives

Donhauser Peter D.o.	director	REGINA-KIRCHMAIER STRASSE 4, KAUFBEUREN 2M 87600
Steffen Thomas	director	FALLMERAYER STR. 19, MUNICH 2M 80796
Christopher U Missling	director, officer: President, CEO, CFO, Treasurer, other: Secretary	61 MOULTON ST, CAMBRIDGE MA 02138
Athanasios Skarpelos	10 percent owner	14,RUE KLEBERG, GENEVA V8 CH-1201
Jiong Ma	director	445 PARK AVENUE, 9TH FLOOR, NEW YORK NY 10022
Elliot Favus	director	51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10091
Sandra Boenisch	officer: PFO & Treasurer	51 WEST 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
Claus Vander Velden	director	PO BOX MUENSTEREIFELER ST., COLOGNE 2M 50937
Bernd Metzner	director	51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
George F Tidmarsh	director, officer: Executive Director
John Robert Chisholm	director	16308 36A AVENUE, SURREY A1 V3S 0X5
William Sean Lowry	director	1172 BAY STREET, SUITE 300, ONTARIO Z4 M5S1L9
David L. Tousley	director	14610 PAWNEE LANE, LEAWOOD KS 66224
Harvey Lalach	director, officer: President CEO CFO	4837 CANYON RIDGE CRESENT, KELOWNA A1 V1W 4A1
Alison E. Ayers	director	27 O'CONNOR CIRCLE, WEST ORANGE NJ 07052